Monday, July 18, 2022

Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response - Cancer Currents Blog

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

 

 

07/15/2022
Male patients with metastatic melanoma don't live as long as females, and their tumors are more likely to become resistant to commonly used treatments. A new study may help explain why: the androgen receptor.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment